The impact of the COVID-19 pandemic on the delivery of primary percutaneous coronary intervention in STEMI.

COVID-19 Primary percutaneous coronary intervention ST-elevation myocardial infarction

Journal

American journal of cardiovascular disease
ISSN: 2160-200X
Titre abrégé: Am J Cardiovasc Dis
Pays: United States
ID NLM: 101569582

Informations de publication

Date de publication:
2021
Historique:
received: 01 07 2021
accepted: 10 10 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 2 12 2021
Statut: epublish

Résumé

The clinical environment has been forced to adapt to meet the unprecedented challenges posed by the COVID-19 pandemic. Intensive care facilities were expanded in anticipation of the pandemic where the consequences include severe delays in elective procedures. Emergent procedures such as Percutaneous Coronary Intervention (PCI) in acute myocardial infarction (AMI) in which delays in timely delivery have well established adverse prognostic effects must also be explored in the context of changes in procedure and public behaviour associated with the COVID-19 pandemic. The aim for this single centre retrospective cohort study is to determine if door-to-balloon (D2B) times in PCI for ST Elevation Myocardial Infarction (STEMI) during the United Kingdom's first wave of the COVID-19 pandemic differed from pre-COVID-19 populations. Data was extracted from our single centre PCI database for all patients that underwent pPCI for STEMI. The reference (Pre-COVID-19) cohort was collected over the period 01-03-2019 to 31-05-2019 and the exposure group (COVID-19) over the period 01-03-2020 to 31-05-2020. Baseline patient characteristics for both populations were extracted. The primary outcome measurement was D2B times. Secondary outcome measurements included: time of symptom onset to call for help, transfer time to first hospital, transfer time from non-PCI to PCI centre, time from call-to-help to PCI centre, time to table and onset of symptoms to balloon time. Categorical and continuous variables were assessed with Chi squared and Mann-Whitney U analysis respectively. Procedural times were calculated and compared in the context of heterogeneity findings. 4 baseline patient characteristics were unbalanced between populations with statistical significance (P<0.05). The pre-covid-19 cohort was more likely to have suffered out of hospital cardiac arrest (OHCA) and had left circumflex disease, whereas the 1 Enhanced infection prevention and control procedures considering the COVID-19 pandemic did not impede the delivery of pPCI in our single centre cohort. The public health impact of the pandemic has been demonstrated with times being significantly impacted by patient related delays. The recovery of public engagement in emergency medical services must become the focus for public health initiatives as we emerge from the height of COVID-19 disease burden in the UK.

Identifiants

pubmed: 34849298
pmc: PMC8611259

Types de publication

Journal Article

Langues

eng

Pagination

647-658

Informations de copyright

AJCD Copyright © 2021.

Déclaration de conflit d'intérêts

None.

Références

Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Am Heart J. 2020 Aug;226:45-48
pubmed: 32497914
Circ Cardiovasc Interv. 2020 Aug;13(8):e009413
pubmed: 32791953
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Lancet. 2017 Aug 19;390(10096):737-746
pubmed: 28778541
Int J Cardiol Heart Vasc. 2021 Apr;33:100736
pubmed: 33644297
Circ Cardiovasc Interv. 2020 Jul;13(7):e009438
pubmed: 32600109
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
J Clin Med. 2020 Jul 10;9(7):
pubmed: 32664309
Eur Heart J. 2011 Jan;32(1):32-40
pubmed: 20709722
Eur J Cardiothorac Surg. 2019 Jan 1;55(1):4-90
pubmed: 30165632
Heart. 2020 Dec;106(23):1805-1811
pubmed: 32868280
Heart. 2017 Jan 15;103(2):117-124
pubmed: 27411838
Br J Cardiol. 2020 Jun 11;27(2):17
pubmed: 35747089

Auteurs

Kristina Frain (K)

Faculty of Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London E1 4NS, UK.

Krishnaraj S Rathod (KS)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Ebrahiem Tumi (E)

London School of Hygiene and Tropical Medicine London WC1E 7HT, UK.

Yang Chen (Y)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.

Stephen Hamshere (S)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Fizzah Choudry (F)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Mohammed M Akhtar (MM)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Miles Curtis (M)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.

Rajiv Amersey (R)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.

Oliver Guttmann (O)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Constantinos O'Mahony (C)

Faculty of Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London E1 4NS, UK.
St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.

Ajay Jain (A)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Andrew Wragg (A)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Andreas Baumbach (A)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Anthony Mathur (A)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Daniel A Jones (DA)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Paul Rees (P)

St Bartholomew's Hospital, Barts Health NHS Trust London EC1A 7BE, UK.
Centre for Cardiovascular Medicines and Devices, Queen Mary University London London E1 4NS, UK.

Classifications MeSH